Bolt Biotherapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Bolt Biotherapeutics wird ein Gewinn- und Umsatzwachstum von 2.6% bzw. 22% pro Jahr prognostiziert, während der Gewinn pro Aktie um 21.1% pro Jahr wachsen soll.

Wichtige Informationen

2.6%

Wachstumsrate der Gewinne

21.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.4%
Wachstumsrate der Einnahmen	22.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding

May 21

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Mar 15

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

May 13

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Dec 01

Bolt Biotherapeutics: A Promised Follow Up

Aug 26

Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M

Aug 10

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:BOLT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	5	-63	N/A	-28	4
12/31/2025	3	-60	N/A	-26	4
12/31/2024	8	-62	N/A	-54	3
9/30/2024	10	-65	-61	-61	N/A
6/30/2024	11	-66	-64	-64	N/A
3/31/2024	11	-63	-63	-63	N/A
12/31/2023	8	-69	-70	-70	N/A
9/30/2023	7	-71	-74	-73	N/A
6/30/2023	7	-77	-71	-70	N/A
3/31/2023	7	-81	-77	-76	N/A
12/31/2022	6	-88	-78	-77	N/A
9/30/2022	5	-95	-79	-76	N/A
6/30/2022	3	-97	-84	-82	N/A
3/31/2022	2	-98	-68	-65	N/A
12/31/2021	1	-99	-59	-57	N/A
9/30/2021	1	-102	-55	-52	N/A
6/30/2021	N/A	-89	-49	-46	N/A
3/31/2021	0	-77	-57	-54	N/A
12/31/2020	0	-61	-51	-47	N/A
9/30/2020	0	-39	-43	-41	N/A
6/30/2020	0	-36	-38	-36	N/A
3/31/2020	0	-32	-31	-30	N/A
12/31/2019	0	-30	-27	-26	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BOLT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: BOLT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: BOLT wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: BOLTDie Einnahmen des Unternehmens (22% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: BOLTDie Einnahmen des Unternehmens (22% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von BOLT in 3 Jahren voraussichtlich hoch sein wird

Bolt Biotherapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 13%

Consensus revenue estimates decrease by 12%, EPS upgraded

Consensus revenue estimates increase by 44%, EPS downgraded

Price target increased by 9.4% to US$5.25

Consensus revenue estimates increase by 21%

Price target decreased by 7.7% to US$4.80

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

High number of new directors

Bolt Biotherapeutics, Inc. Announces Changes to Its Board of Directors

Consensus EPS estimates fall by 13%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bolt Biotherapeutics Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Requirement under Nasdaq Listing Rule 5450(a)(1)

Bolt Biotherapeutics Receives Written Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Requirement under Nasdaq Listing Rule 5450(a)(1)

Pomerantz Law Firm Announces the Filing of A Class Action Against Bolt Biotherapeutics, Inc. and Certain Officers - BOLT

High number of new directors

Little Excitement Around Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Revenues As Shares Take 29% Pounding

Consensus revenue estimates decrease by 12%, EPS upgraded

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bolt Biotherapeutics, Inc., Annual General Meeting, Jun 12, 2024

Consensus revenue estimates increase by 44%, EPS downgraded

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Needs To Drive Business Growth Carefully

Price target increased by 9.4% to US$5.25

Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating Bdc-1001 in Patients with Her2-Positive Breast Cancer Previously Treated with Enhertu

Consensus revenue estimates increase by 21%

Bolt Biotherapeutics, Inc. Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress

Price target decreased by 7.7% to US$4.80

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Bolt Biotherapeutics, Inc. Appoints Laura Berner to Board of Directors

Is Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$6.40

Bolt Biotherapeutics: A Promised Follow Up

Consensus revenue estimates increase by 36%

Bolt Biotherapeutics GAAP EPS of -$0.61 beats by $0.08, revenue of $1.39M beats by $0.89M

We're Keeping An Eye On Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Bolt Biotherapeutics, Inc.(NasdaqGS:BOLT) dropped from Russell 2500 Index

Price target decreased to US$11.50

High number of new directors

We're Not Very Worried About Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Rate

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Bolt Biotherapeutics, Inc. Announces Resignation of David Dornan as Chief Scientific Officer, Effective from March 11, 2022

Price target decreased to US$13.67

Bolt Biotherapeutics Doses First Patient with BDC-1001 in Combination with OPDIVO® (nivolumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of HER2-Expressing Solid Tumors

Less than half of directors are independent

We Think Bolt Biotherapeutics (NASDAQ:BOLT) Can Afford To Drive Business Growth

Consensus revenue estimates fall to US$1.00m

Bolt Biotherapeutics: Pioneering A New Class Of Immunotherapies

We're Hopeful That Bolt Biotherapeutics (NASDAQ:BOLT) Will Use Its Cash Wisely

Bolt Biotherapeutics, Inc.(NasdaqGS:BOLT) dropped from Russell 3000E Growth Index

Bolt Biotherapeutics, Inc. announced that it has received $15 million in funding from Genmab A/S

Bolt Biotherapeutics, Inc. Presents Preliminary Results from Phase 1/2 Trial of Lead HER2-targeting Boltbody™ ISAC BDC-1001 at ASCO 2021

Bolt Biotherapeutics, Inc. announced that it expects to receive $15 million in funding from Genmab A/S

Full year 2020 earnings released: US$28.89 loss per share (vs US$15.29 loss in FY 2019)

Bolt Biotherapeutics, Inc. has completed an IPO in the amount of $230 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken